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nImproving the metabolic fidelity of cancer models with
a physiological cell culture medium
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Gabriela Kalna1, Colin Nixon1, Karen Blyth1,2, Eyal Gottlieb1,3, Saverio Tardito1,2*
Currently available cell culture media may not reproduce the in vivo metabolic environment of tumors. To demon-
strate this, we compared the effects of a newphysiologicalmedium, Plasmax,with commercialmedia.Weprove that
the disproportionate nutrient composition of commercial media imposes metabolic artifacts on cancer cells. Their
supraphysiological concentrations of pyruvate stabilize hypoxia-inducible factor 1a in normoxia, thereby inducing a
pseudohypoxic transcriptional program. In addition, their arginine concentrations reverse the urea cycle reaction
catalyzed by argininosuccinate lyase, an effect not observed in vivo, and prevented by Plasmax in vitro. The capacity
of cancer cells to form colonies in commercial media was impaired by lipid peroxidation and ferroptosis and was
rescued by selenium present in Plasmax. Last, an untargeted metabolic comparison revealed that breast cancer
spheroids grown in Plasmax approximate the metabolic profile of mammary tumors better. In conclusion, a phys-
iological medium improves the metabolic fidelity and biological relevance of in vitro cancer models.loa
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 INTRODUCTION
It seems obvious that the nutrient composition of the culturemedium
affects the phenotypic behavior of cells, their response to stresses and
stimuli, epigenotype, and transcriptome. However, until recently (1–5),
very little attention has been paid to perfecting the formulation of historic
media. The vastmajority of biomedical researchers use cell culturemedia
thatwere not designed to reproduce the physiological cellular environ-
ment but were formulated to enable the continued culture of cells with
minimal amounts of nutrients and serum (i.e., Eagle’sminimal essential
medium). Later, these media were modified bymultiplying the concen-
tration of selected nutrients, such as glucose and glutamine, by a factor
of 4, to avoid nutrient exhaustion when leaving the culture unattended
for longer time periods [i.e., Dulbecco’s modified Eagle’s medium
(DMEM)]. Therefore, it is not surprising that several recent reports high-
light discrepancies between in vitro and in vivo cancer cell metabolism
(6, 7). We have previously designed a medium containing amino acids,
glucose, andpyruvate at physiological concentrations (2,3).More recently,
a culture medium was formulated on the basis of the composition of
human blood, and its use proved to profoundly affect in vitro cancer
cell metabolism (1).
Aiming to investigate and reduce the gap between in vitro observa-
tions and tumor biology, we implemented a complex culture medium,
herein called Plasmax, composed of more than 50 nutrients and meta-
bolites at the concentration normally found in human blood, and we
directly compared its effects on cultured cells against standard commercial
media. This new medium includes metabolites with marginal nutritional
value, but whose physiological relevance to cellular metabolism cannot
be discounted. This is exemplified by uric acid, the end product of pu-
rine catabolism, which inhibits pyrimidine synthesis, a pathway central
for cancer cell anabolism (1). In this study, we compare triple-negative
breast cancer (TNBC) cell lines cultured inPlasmax or inDMEM-F12, a
commercially available, nutrient-richmedium.Weshow that the adoption
of amore physiological culturemedium,which includes themicronutrientselenium, substantially influences the colony-forming capacity of cancer
cells by preventing ferroptosis. This form of cell death caused by iron-
dependent lipid peroxidation is counteracted by selenoproteins, such
as glutathione peroxidase 4 (GPX4), whose expression and activity are
dependentonseleniumavailability (8,9). Furthermore, the transcriptional
and metabolic phenotypes of cells cultured in Plasmax are reprogrammed
in a way that is largely independent of the cell proliferation rate. This sug-
gests that the supraphysiological concentrations of nutrients (e.g., glucose
and glutamine) present inmost commercialmedia are not essential to sus-
tain cell proliferation and misshape the metabolism of cancer cells. This
aspect was studied in depth by relating the availability of nutrients in the
media to their exchange rates and intracellular levels. Last, by means of an
untargeted metabolomics approach, we compared the profiles of breast
cancer cells cultured in Plasmax and DMEM-F12 with orthotopic xeno-
grafts grown in mice, providing evidence that Plasmax more closely reca-
pitulates the metabolic environment of tumors.RESULTS
The formulation of a physiological medium: Plasmax
To design a chemically definedmediumwith nutrients andmetabolites at
concentrationsnormally found in thebloodof healthyhuman individuals,
we consulted a publicly available database (www.serummetabolome.ca).
On the basis of the normal concentration range reported for human
blood (meeting the arbitrary threshold of 2 mM), commercial availa-
bility, and chemical stability, we selected proteinogenic and nonpro-
teinogenic amino acids, amino acid derivatives, and other components
as reported in table S1. These compounds were dissolved in stock so-
lutions and added to Earle’s balanced salt solution (EBSS), together
with salts, vitamins, and trace elements, to obtain a ready-to-use cell
culture medium, herein called Plasmax (see Materials and Methods
and table S1 for details on formulation and stock solutions). Despite
having been designed and developed independently, the composition
of Plasmax is similar to the recently reported human plasma-like me-
dium (HPLM) (table S1) (1), thus cross-validating the methods used
to formulate these physiological media. To minimize the influence of
components contributed by the bovine serum, all the experiments
were performed by supplementing the media with 2.5% fetal bovine
serum (FBS) unless otherwise indicated.1 of 14
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 To compare the effect of different culture media on the phenotypic
behavior of cells, we selectedDMEM-F12, a commercially availableme-
dium that is richer than MEM and DMEM in terms of nutrient
composition and is suitable for growth of a wide range of cell types even
under low-serum conditions. The direct comparison of the formulation
of Plasmax and DMEM-F12 is reported in Fig. 1A. Of note, while glu-
cose and glutamine together account for almost three-quarters of the
entire pool of nutrients in DMEM-F12 (24.5 mM), these components
contribute less than half of the whole pool in Plasmax (14.5 mM, Fig.
1B). Moreover, 35% of the total nutrient availability within Plasmax is
made up of components that are not present in DMEM-F12, thereby
providing more nutritional options for the cells.
Plasmax sustains breast cancer cell growth in vitro and
increases colony formation capacity
We tested the effects of Plasmax andDMEM-F12 on the human TNBC
cell lines BT549, CAL-120, and MDA-MB-468 that were routinely
cultured in DMEM-F12 supplemented with 10% FBS. Cells were pre-
incubated for at least 48 hours in the respective media, both containing
2.5% FBS, to allow adaptation to the experimental conditions. To pre-
vent exhaustion of the nutrients that are avidly consumed by cancer cells
and present at lower concentrations in Plasmax than in DMEM-F12
(e.g., glucose and glutamine), the ratio between the volume of medium
and number of cells was maintained in excess of 1ml/100,000 cells/day.
In normoxia, all cell lines proliferated at comparable rates in the two
media, with only the MDA-MB-468 cells showing a trend toward
slower proliferation in Plasmax (Fig. 1C). To investigate this further,
we cultured MDA-MB-468 cells for several passages in the two media.
Their doubling time was calculated at each passage and demonstrated a
1.5-fold slower growth rate in Plasmax compared to DMEM-F12 (Fig.
1D). Alongside the effect on proliferation, Plasmax affected the mor-
phology of MDA-MB-468 cells. Phase contrast microscopy indicated
that, when cultured in Plasmax, MDA-MB-468 cells were flatter, and
the associations between neighboring cells appeared to be looser than
when these cells were grown inDMEM-F12 (Fig. 1E). In addition, when
cells were plated at lowdensity, Plasmax increased the colony formation
capacity of all cell lines, with themost pronounced effect being observed
in MDA-MB-468 cells (Fig. 1, F to H). Consistently, a 2-day pre-
incubation with Plasmax was sufficient to slightly increase the number
of colonies formed by BT549 and MDA-MB-468 cells when incubated
in DMEM-F12 (Fig. 1H). These results show that the effect of Plasmax
on cells persists following its withdrawal, suggesting the accumulation
of amedium component or the triggering of signaling pathways advan-
tageous for colony formation.
Identification of sodium selenite as the Plasmax component
enhancing the colony formation capacity of TNBC cells
To assess whether Plasmax increased or DMEM-F12 suppressed the
colony formation capacity, we incubated MDA-MB-468 cells in a 1:1
mixture of bothmedia (Fig. 2A). Since this resulted in a colony number
comparable to that obtained in Plasmax, we further investigated which
component of Plasmax was responsible for stimulating colony forma-
tion. By systematically adding the mixed stock solutions (table S1) and,
subsequently, the individual components of Plasmax to DMEM-F12,
we identified sodium selenite as the component of Plasmax, which
was sufficient to increase colony formation in MDA-MB-468 (Fig.
2A), BT549, andCAL-120 cells (fig. S1). The colony-stimulating activity
of selenite was dose dependent, with the maximal effect observed at
~25 nM (Fig. 2, B and C), and evident when the FBS supplementa-Vande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019tion was lower than 10% (Fig. 2F). In line with the results obtained by
comparing the effects of Plasmax and DMEM-F12 (Fig. 1, C and F to
H), selenite promoted survival and proliferation of cells seeded at low
density, while its effect progressively diminishedwith the increase of the
number of cells seeded (Fig. 2, D and E). Selenium is incorporated into
the active site of selenoproteins as selenocysteine, and hence, it modu-
lates the antioxidant capacity of cells. We therefore tested the effects of
antioxidants such asN-acetylcysteine and the vitaminEderivative, Trolox.
Both compounds significantly rescued the area covered by colonies
in the absence of selenium supplementation, proving that oxidative
stress hinders colony formation (Fig. 2, G to I). Glutathione peroxidases
(GPXs) are antioxidant enzymes whose activity largely depends on the
presence of selenium in their active site. In particular, since GPX4 is
regulated by selenium availability (8), we tested the effects of selenite
supplementation on GPX4 levels in MDA-MB-468 cells. Independent
of the cell density, the expression (Fig. 2J) and activity (Fig. 2K) ofGPX4
were markedly increased in the presence of selenite. Next, to investigate
the role of GPX4 in the colony-forming process, we seeded cells at low
and high densities and incubated them with selenite and (1S,3R)-RSL3,
a specific GPX4 inhibitor. Despite selenite supplementation, this com-
pound significantly decreased the capacity of cells to form colonies
when seeded at low density without affecting high-density cell cultures
(Fig. 2, L andM). This suggested that high GPX4 activity is required to
maintain the redox balance in isolated cells but is dispensable in more
confluent cultures. We then measured the level of peroxidized lipids, a
preferential substrate for GPX4, using the fluorescent probe BODIPY
C11 581/591. Lipid peroxidation was significantly higher in cells seeded
at low cell density in the absence of selenite compared to similar cell
cultures supplemented with selenite (Fig. 2N). Moreover, selenium-
deprived cells showed significantly higher levels of lipid peroxidation
when seeded at low cell density compared to high-density cell cultures
(Fig. 2N). These results demonstrate that selenium supplementation
prevents lipid peroxidation bymaintaining high levels of GPX4 activity,
and thereby increases the fitness of breast cancer cells to form colonies.
Notably, more confluent cells also require selenium for maintaining
their redox balance and viability if challenged with a peroxidizing agent
such as tert-butylhydroperoxide (t-butOOH; Fig. 2, N and O). Since
GPX4 inhibition and lipid peroxidation have been shown to cause fer-
roptosis (9), we assessed whether this type of iron-dependent cell death
could explain the defect in colony formation of selenium-deprived
cells. Therefore, a colony-forming assay was performed by seeding
cells at low density in the presence of an iron chelator, deferoxamine,
or a ferroptosis inhibitor, liproxstatin-1. The results show that the
colony-forming capacity in the absence of selenite was significantly
increased by deferoxamine and completely rescued by liproxstatin-
1 (Fig. 2, P to S). Together, we demonstrated that breast cancer cells
seeded at low density in the absence of selenium undergo cytotoxic
lipid peroxidation, resulting in ferroptotic cell death (Fig. 2T). In ad-
dition, we elucidated the mechanism through which a cell culture
medium composition can significantly affect the results obtained
in assays that are commonly used in biomedical research.
Plasmax normalizes the pseudohypoxic state of cells
cultured in commercial media
To investigate the effects of the medium composition on gene expres-
sion, we cultured BT549, CAL-120, andMDA-MB-468 cells in Plasmax
or DMEM-F12 in the presence of 21% or 0.1% O2 (normoxia and hy-
poxia, respectively), and we evaluated the transcriptional response by
RNA sequencing (RNA-seq). First, the RNA profiles in normoxia were2 of 14
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Fig. 1. Plasmax sustains cancer cell growth and increases colony formation. (A and B) Comparison of the formulation of Plasmax and DMEM-F12. na (not applicable)
refers to components not present inDMEM-F12, with the exception of linoleate, putrescine, lipoic acid, and thymidine, which are not present in Plasmax. (C) Cell number at the
end of a proliferation assay with BT549, CAL-120, andMDA-MB-468 cells, performed in Plasmax or DMEM-F12 under normoxic (N) and hypoxic (H) conditions, 21 and 0.1%O2,
respectively. Means ± SEM; n = 3 independent experiments. (D) Doubling time ofMDA-MB-468 cells as determined after each of the 10 consecutive passages in either DMEM-
F12 or Plasmax.Means ± SEM. (E) Micrographs showing themorphology ofMDA-MB-468 cells cultured in DMEM-F12 or Plasmax for eight passages. (F) Representative images
and (G and H) quantification of a colony formation assay performed with BT549, CAL-120, and MDA-MB-468 cells preincubated (2 days), seeded at 500 cells per well, and
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experiment, and P values refer to a two-tailed t test for paired homoscedastic samples.Vande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019 3 of 14
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Fig. 2. The Plasmax component sodium selenite prevents ferroptosis and thereby enhances the colony formation capacity of TNBC cells. (A) Images of colony
formation assays performed with MDA-MB-468 cells seeded 500 cells per well and incubated for 14 days in 1:1 DMEM-F12/Plasmax mix or in DMEM-F12 supplemented with
the different mixed stock solutions or individual components of Plasmax. Images are representative of three independent experiments. (B) Representative images and
(C) quantification of colony formation assays performedwithMDA-MB-468 cells seeded at 500 cells per well in DMEM-F12 with different concentrations of Na2SeO3 and
incubated for 14 days. Means ± SEM; n = 3 independent experiments. (D) Representative images and (E) quantification of the colony formation assays performed with
MDA-MB-468 cells seeded at the indicated cell density and incubated for 7 days. Means ± SEM; n = 3 independent experiments. (F) Quantification of colony formation
assays performedwithMDA-MB-468 cells seeded at 5000 cells per well and incubated for 7 days in DMEM-F12 supplemented with FBS and 50 nMNa2SeO3, as indicated.
Means ± SEM; n = 3 independent experiments. (G) Representative images and (H and I) quantification of colony formation assays performed with MDA-MB-468 cells
seeded at 5000 cells per well and incubated for 7 days in DMEM-F12 with 50 nMNa2SeO3, 1mM N-acetylcysteine (NAC), or 100 mMTrolox, as indicated. Means ± SEM; n =
3 independent experiments. (J) Western blot showing GPX4 levels in MDA-MB-468 cells seeded at low (2000 cells/cm2) or high (10,000 cells/cm2) density and incubated
in DMEM-F12 for 3 days with 50 nMNa2SeO3, as indicated. Images are representative of three independent experiments. (K) GPX activitymeasured in MDA-MB-468 cells
seeded and incubated as for (J). Means ± SEM; n = 3 independent experiments. (L) Representative images and (M) quantification of colony formation assays performed
with MDA-MB-468 cells seeded at 5000 cells per well (L) or at 50,000 cells per well (H) and incubated for 7 days in DMEM-F12 supplemented with 50 nMNa2SeO3 and 250 nM
(1S,3R)-RSL3. Means ± SEM; n = 2 independent experiments. (N) Lipid peroxidation levels of MDA-MB-468 cells seeded as in (J) and incubated in DMEM-F12 for 48 hours
with 50 nM Na2SeO3 and for the last hour with 50 mM t-butOOH, as indicated. At the end of the incubation, 1 mM BODIPY 581/591 C11 was added to the cells for 15 min.
Means ± SEM; n = 3 or 4 independent experiments. (O) Representative images of MDA-MB-468 cells seeded at 10,000 cells/cm2 and incubated in DMEM-F12 with
Na2SeO3 for 72 hours and for the last 24 hours with 50 mM t-butOOH, as indicated. Images are representative of three independent experiments. (P and R) Representative
images and (Q and S) quantification of colony formation assays performed with MDA-MB-468 cells seeded at 5000 cells per well and incubated for 7 days in DMEM-F12
supplementedwith 50 nMNa2SeO3, 2.5 mMdeferoxamine, and 50 nM liproxstatin-1 (Lip-1), as indicated.Means± SEM;n=2 (P andQ) or n=3 (R and S) independent experiments.
(T) Schematic representation of the factors affecting the colony-forming capacity of TNBC cells. “X” refers to a factor present in themediumof confluentMDA-MB-468 cells and not
yet identified. (F, H, I, K, M, N, Q, and S) Each dot represents an independent experiment, and P values refer to a two-tailed t test for paired homoscedastic samples.Vande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019 4 of 14
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 compared by a principal components analysis (PCA). While compo-
nents 1 to 3 mainly separated the individual cell lines, component 4
separated the cells according to the culture media (Fig. 3A and fig.
S2). In particular, more than a thousand genes were differentially regu-
lated by the twomedia inMDA-MB-468 cells (Fig. 3B). However, of all
the genes that were significantly regulated by the media in at least one
cell line, only 5% of genes were coordinately regulated in two or more
cell lines, and only four genes (INHBA, SEPW1, LAMC2, and MT1E)
were coordinately regulated in all three cell lines (Fig. 3, B and C). This
indicates that the broad transcriptional response induced by a different
nutritional environment is cell line specific, even within a group of cells
that originate from the same cancer subtype (i.e., TNBC).
Subsequently, the effect of the culture media on the response to hy-
poxia was investigated. Hypoxia reduced the proliferation of all cell
lines.However, Plasmax provided aminor growth advantage to hypoxic
BT549 and CAL-120 cells (Fig. 1C). In addition, in BT549 cells, the
transcriptional response to hypoxia was medium dependent. A correla-
tion analysis demonstrated that genes that were significantly induced in
hypoxia in BT549 cells were down-regulated by Plasmax (compared to
DMEM-F12) under normoxic conditions (Fig. 3D). This indicated a
hypoxic gene expression signature in cells cultured inDMEM-F12, even
under normoxia. Several genes following this inverse correlation are
established hypoxia-inducible factor 1a (HIF1a) targets, such as CA9,
TXNIP, PDK1, and BNIP3. While the expression of these genes was in-
duced by hypoxia independently of the media, their expression levels
under normoxic conditions were significantly decreased in Plasmax
compared to DMEM-F12 (Fig. 3E). Consistent with this regulatory pat-
tern, the protein levels of HIF1a and its target PDK1 under normoxia
were reduced in BT549 cells when they were cultured in Plasmax (Fig.
3F). Of note, the levels of normoxic HIF1awere comparable in all three
cell lines when cultured in Plasmax (Fig. 3G). To test whether the effect
on the normoxic stabilization of HIF1a was specific to DMEM-F12, we
incubated BT549 cells in two other commonly used commercial media
(i.e., DMEMand RPMI 1640). Bothmedia increased the normoxic levels
of HIF1a even further (Fig. 3H). These results demonstrate that non-
physiological media can impose a chronic pseudohypoxic state and that
this is avoided by culturing cells in Plasmax.
Given the large number of differences between the composition of
DMEM-F12 and Plasmax, a systematic elimination/addition approach
was used, and pyruvate was identified as the factor regulating HIF1a in
normoxia. The levels of HIF1a in BT549 cells incubated in Plasmax,
DMEM-F12, DMEM, and RPMI 1640 positively correlated with the
pyruvate concentrations supplemented in those media (0.1, 0.5, 1,
and 1 mM, respectively; Fig. 3H). Furthermore, pyruvate was sufficient
to induce HIF1a levels in a dose-dependent manner in different media
(Fig. 3I). Together, these results show that supraphysiological concentra-
tions of pyruvate, which are commonly found in commercial media, do
not affect the response of cells to oxygen limitation, but can lead to the
stabilization of HIF1a, inducing a pseudohypoxic response in normoxia.
The metabolism of cancer cells is skewed by the availability
of nutrients in the medium
Next, we compared the effects of Plasmax and DMEM-F12 on cell me-
tabolism. First, we determined the exchange rates of nutrients and me-
tabolites between cells andmedia (Fig. 4A). For bothmedia, glucosewas
the most consumed nutrient, and lactate was the most abundantly re-
leased metabolite. The exchange rates of glucose and lactate were not
significantly different in the two media. Since the concentration of
glucose is 3-fold higher in DMEM-F12 than in Plasmax (17.5 andVande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 20195.56 mM, respectively), we can conclude that, under these conditions,
the rate of glucose fermentation is independent of its extracellular avail-
ability. In contrast, the consumption of glutamine was affected by the
media. All three cell lines consumed markedly less glutamine in Plas-
max, where it is supplemented at 0.65 mM, compared to DMEM-F12,
which contains 2 mM glutamine. We also found a correlation between
availability and consumption for nutrients other than glutamine. For all
cell lines, a significant, positive correlation was found between theme-
dium concentrations of the neutral proteinogenic amino acids and the
rate at which they were consumed and/or secreted (Fig. 4B). In par-
ticular, all cell lines released alanine in DMEM-F12 but consumed it
in Plasmax, where it is 10-fold more concentrated (0.05 mM versus
0.51 mM). Since alanine is central for the transfer of nitrogen be-
tween amino acids (i.e., transamination), we tested whether the ba-
lance of aminoacidic nitrogenwas affected by themedia (Fig. 4C). The
net consumption of amino acid–derived nitrogen was higher in
DMEM-F12 compared to Plasmax, showing that, in DMEM-F12,
the release of alanine does not compensate for the increased metabo-
lism of other amino acids. In line with this, the intracellular concen-
tration of glutamine, another major nitrogen carrier, was elevated in
DMEM-F12 compared to Plasmax in the three cell lines (Fig. 4D).
Together, these results show that supplementing media with concen-
trations of amino acids that deviate from those found in serum causes
proportional changes in their uptake/release and metabolism. More-
over, these changes occur without pronounced effects on proliferation
(Fig. 1C), indicating that an increase in amino acid consumption does
not predict its essentiality for growth.
All cell lines showed decreased intracellular levels of pyruvate when
cultured in Plasmax comparedwithDMEM-F12 (Fig. 4E). As shown in
Fig. 3 (G to I), the supraphysiological pyruvate concentration of com-
mercial media stabilizes HIF1a, specifically in BT549 cells. In line with
this, BT549 cells were also distinct from the other two lines in terms of
pyruvate metabolism. While CAL-120 and MDA-MB-468 cells
consumed pyruvate from DMEM-F12 (where it is supplemented at
500 mM), and released it in Plasmax (where it is present at 100 mM),
BT549 cells exported large quantities of pyruvate in both media (Fig.
4A). In addition, BT549 cells cultured in DMEM-F12 showed high
pyruvate/lactate and NAD+/NADH ratios, which were both normal-
ized by Plasmax to those observed in CAL-120 and MDA-MB-468
cells (Fig. 4, F and G). Unexpectedly, the pyruvate-dependent stabili-
zation of HIF1a in BT549 cells cultured in DMEM-F12 occurred de-
spite significantly elevated levels of a-ketoglutarate, an obligate
substrate of the prolyl-hydroxylases that promotes the degradation
of HIF1a (Fig. 4H).
The medium-dependent effects on metabolic processes are cell line
specific, supporting the view that the nutritional environment rewires
cellmetabolismbased on the (epi)genome. Thiswas further exemplified
when studying arginine metabolism. Argininosuccinate is an inter-
mediate of the urea cycle produced by argininosuccinate synthetase
1 (ASS1) from citrulline and aspartate and was found to be decreased
in several cancer cell lines when cultured in a physiological culture me-
dium (1). The intracellular levels of argininosuccinate in CAL-120 cells
were substantial in DMEM-F12 but close to the detection limit when
cultured in Plasmax (Fig. 4I). Since the gene encoding argininosuccinate
synthetase 1, ASS1, undergoes epigenetic silencing in multiple types of
cancer (10), we tested its protein expression, which was barely detect-
able in CAL-120 cells (Fig. 4J). These results indicate that the levels of
ASS1 and its product, argininosuccinate, were uncoupled in these cells
when cultured in DMEM-F12. Arginine is 10-fold more abundant in5 of 14
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Fig. 3. Plasmax induces cell line–specific transcriptomic alterations and prevents the pseudohypoxic gene expression signature of cells cultured in commer-
cial media. (A) PCA of gene expression obtained from RNA-seq data of BT549, CAL-120, and MDA-MB-468 cells cultured in Plasmax or DMEM-F12, in normoxia. n = 3. Each
symbol represents an independent experiment. (B) Venn diagram showing the number of genes that were differentially regulated in these cell lines when cultured in Plasmax
and DMEM-F12. (C) Heat map of genes that were significantly [false discovery rate (FDR) of 10%] and coherently regulated (absolute log2 fold change ≥ 0.585) by culturing cells
in Plasmax, in normoxia, in at least two of three cell lines. n = 3, log2 (mean fold change). (D) Correlation analysis of genes regulated by hypoxia in Plasmax (y axis) and genes
regulated by Plasmax in normoxia (x axis). Each dot represents the mean of three independent experiments. (E) Expression levels of HIF1a target genes CA9, TXNIP, PDK1, and
BNIP3 in BT549 cells relative to control condition (normoxia, DMEM-F12). Means ± SEM; n = 3, each dot represents an independent experiment, and P values refer to a two-tailed
t test for unpaired homoscedastic samples. (F) Western blot showing HIF1a levels in BT549 cells in Plasmax (P) or DMEM-F12 (D), in normoxia (N) and hypoxia (H). (G) Western
blot showing HIF1a levels in BT549, CAL-120, and MDA-MB-468 cells cultured in DMEM-F12 or Plasmax in normoxia. (H) Western blot showing HIF1a levels in BT549 cells
cultured in normoxia in DMEM-F12, Plasmax, DMEM, and RPMI 1640. (I) Western blot showing pyruvate-dependent HIF1a levels in BT549 cells, cultured in DMEM-F12, Plasmax,
and DMEM in normoxia. (F to I) Images are representative of three independent experiments. P values refer to a two-tailed t test for unpaired homoscedastic samples.Vande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019 6 of 14
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 DMEM-F12 (0.699mM) than in Plasmax (0.064mM), and the higher
extracellular concentration translates into increased intracellular argi-
nine levels (Fig. 4K). While argininosuccinate lyase (ASL) produces
arginine and fumarate from argininosuccinate in the urea cycle, we
hypothesized that the supraphysiological levels of arginine present
in DMEM-F12 could reverse the reaction catalyzed by ASL and pro-
duce argininosuccinate directly from arginine in ASS1-deficient cells
(Fig. 4L). This hypothesis was tested by incubating CAL-120 cells in
Plasmax orDMEM (commercially available without arginine) supple-
mented with 13C6 arginine to reach a concentration of 0.7 mM. This
increased the intracellular levels of 13C6 arginine (fig. S3A) and argi-
ninosuccinate (Fig. 4M). Confirming our hypothesis, the 13C6 isoto-
pologue of argininosuccinate accounted for more than 95% of its total
intracellular pool, while less than 0.5% was derived from citrulline via
the canonical urea cycle, where one of the six carbons of arginine is lost
to produce urea (13C5 argininosuccinate; Fig. 4M). These results dem-
onstrate that ASL activity is reversed under these conditions and ex-
plain the increased levels of argininosuccinate in CAL-120 cells
cultured in DMEM-F12. To test whether this metabolic anomaly
was specific to ASS1-deficient cells, 13C6 arginine was also traced in
ASS1-proficient cell lines (BT549 andMDA-MB-468). The isotopolo-
gue distribution of argininosuccinate demonstrates that, upon expo-
sure to supraphysiological levels of arginine, ASL activity is reversed in
those cells as well (Fig. 4, N and O). Whereas the presence of 13C5 or-
nithine indicated arginase (ARG) activity in all three cell lines (fig. S3B),
13C5 citrulline was not detected under any condition (fig. S3C), indicat-
ing that either the mitochondrial carbamoyl phosphate synthase
1 (CPS1) or ornithine transcarbamylase (OTC) is not active. Con-
sistently, also in ASS1-proficient cells cultured in DMEM supplemented
with 13C6 arginine, the entire argininosuccinate pool consisted of
13C6
argininosuccinate (Fig. 4,N andO).However,when cultured inPlasmax,
most of the argininosuccinate was derived from citrulline uptaken from
the medium (13C0 argininosuccinate; Fig. 4, N and O). This observation
suggests that, under physiological conditions, these ASS1-proficient cells
depend on the exogenous availability of citrulline for the production of
argininosuccinate. Overall, we show that concentrations of arginine
commonly present in cell culture media reverse a reaction of the urea
cycle in TNBC cells and thereby mask the metabolic hallmarks of
ASS1-deficient cells. Moreover, our findings highlight that, in the ab-
sence of exogenous citrulline (i.e., in commercialmedia), ASS1-proficient
breast cancer cells also produce argininosuccinate mainly via reversed
ASL activity.
Cells cultured in Plasmax better recapitulate the metabolic
signature of tumors
Next, we compared the metabolic profiles of CAL-120 cells cultured in
vitro, inDMEM-F12 andPlasmax, with the profile of CAL-120–derived
mammary tumors. For this purpose, CAL-120 cells were grown as an
adherent monolayer [two-dimensional (2D)] and in suspension as
spheroids (3D) in the two differentmedia. To obtain orthotopic tumors,
we implanted CAL-120 cells, cultured inDMEM-F12 asmonolayers, in
the mammary fat pad of mice (Fig. 5A). The liquid chromatography
tandem mass spectrometry (LC-MS/MS) results were analyzed by
means of an untargeted metabolomics approach, which allowed the
comparison of samples with different biologicalmatrices. By combining
the ions detected in both positive and negative modes, this analytical
approach identified ~100 compounds that were analyzed with a PCA
(Fig. 5B). The PCA grouped the samples according to the biological
conditions. For both 2D and 3D cultures, cells grown in Plasmax wereVande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019clearly separated from cells grown in DMEM-F12. Tumor samples
clustered away from the in vitro conditions, showing that the variation
between the in vivo and in vitrometabolic profiles exceeds the variation
observed between tumors grown in different animals. Of the in vitro
conditions, cells cultured in 3D in Plasmax clustered closest to the tu-
mor (Fig. 5, B and C), indicating that, by adopting a 3D culture method
and physiological medium, the overall metabolic phenotype of tumors
can be better approximated.
As shown in Fig. 4 (L to O), supraphysiological concentrations of
arginine cause the reversal of one of the reactions of the urea cycle in
vitro. This resulted in the accumulation of argininosuccinate in ASS1-
deficient cells cultured inDMEM-F12 but not in Plasmax (Fig. 4, I and J).
To test whether this rewiring of the urea cycle was relevant in vivo, we
assessed the levels of intermediates of the urea cycle in tumors and
cultured cells. Arginine levels were comparable between tumors and
cells cultured in Plasmax, but were ~4-fold higher in cells cultured in
DMEM-F12 (Fig. 5D). As a consequence of the different arginine avail-
ability, the level of argininosuccinate was higher in cells cultured in
DMEM-F12 comparedwith tumors (Fig. 5E). The levels of argininosuc-
cinate were found to be lower in cells cultured in Plasmax than in
tumors, a difference thatmay be explained by the intratumoral presence
of ASS1-proficient stromal cells. An immunohistochemistry (IHC)
analysis confirmed the ASS1 deficiency of cancer cells and showed
ASS1-positive stromal cells and vascular endothelium (11) in tumor
tissue (Fig. 5, G to I). In addition, the argininosuccinate/citrulline ratio,
a further readout of ASS1 activity, wasmarkedly higher in cells cultured
inDMEM-F12comparedwith the tumororwith cells cultured inPlasmax
(Fig. 5F). Together, these results demonstrate that the reversed activity
of ASL, caused by the supraphysiological concentration of arginine in
commercial media, is an artifactual phenotype that is not relevant to
tumor biology and that can be avoided by using a culture medium
based on physiology such as Plasmax.DISCUSSION
Current cancer research heavily relies on results obtained using cell
culture. Addressing the many discrepancies between in vivo biology
and cell-based models (e.g., nonphysiological media composition,
lack of waste product removal, and the often hyperoxic
environment) may improve the reliability of results obtained in vitro.
This study objectively shows that efforts to refine culture conditions
improve the robustness and fidelity of in vitro cancer cell models. It
demonstrates that the culture medium formulation significantly
affects the results obtained in commonly used cell biology assays,
such as those testing colony formation and gene expression. Plasmax
is a newly formulated medium composed of nutrients and metabo-
lites at the concentration normally found in human plasma. Here, we
provided the composition and procedure to produce Plasmax as a
resource to address specific physiopathological questionsmore accu-
rately. The use of this, as well as another medium independently for-
mulated on a similar rationale (1), could help to explain some of the
metabolic discrepancies between results obtained with in vitro cell
culture and in vivo models (4, 6, 7). The present study and Cantor
et al. (1) show that the disproportionate and nonphysiological con-
centrations of nutrients typically found in commercial media skew
the metabolism of cancer cells at both the intracellular and exchange
flux levels (Fig. 4) and generate undesired artifactual phenotypes
(Figs. 3 to 5). These insights should be considered when designing
studies that aim to identify the dependency of cancer cells on specific8 of 14
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 nutrients or metabolic pathways (i.e., metabolic addictions) or when
investigating the effects of antimetabolites.
To provide proof of concept that the use of physiological media
can also unveil novel biological findings, we mechanistically eluci-
dated the causes underlying phenotypic, transcriptomic, and meta-
bolic differences found in cells cultured in Plasmax and DMEM-F12.
First, we revealed a novel role for sodium selenite as a stimulator of
the colony formation capacity of breast cancer cells (Fig. 2). Seleni-
um, one of the essential mineral nutrients typically contributed to
culturemedia by FBS, is supplemented to Plasmax as sodium selenite
and is incorporated in selenoproteins such as GPXs. The expression
of GPX4 was increased upon selenite supplementation, and its high
activity prevented lipid peroxidation. Ferroptosis, a type of cell death
caused by iron-dependent lipid peroxidation, was identified as the
cause of the compromised colony formation capacity of cells cultured
in DMEM-F12 with reduced FBS and was prevented by antioxidants,
iron chelators, and selenite.While the potential anticancer and cancer-
preventive effects of selenium supplementation have been the subject
of many studies (12), our results indicate that sodium selenite mayVande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019provide a cell-autonomous survival advantage to isolated cancer cells
in a hostile environment. Of note, selenite (or Plasmax) did not confer
any survival or growth advantage when cells were cultured as more
confluent cultures (Figs. 1C and 2, D and E). We found that the
conditioned medium of MDA-MB-468 cells cultured at high density
rescued the colony-forming capacity of selenium-deprived cells, sug-
gesting that cells secrete a yet unidentified, protective factor. The
translational potential of our findings is substantiated by the increased
incidence of metastases observed in a mouse model of breast cancer
upon dietary supplementation of sodium selenite (13) and calls for
further investigation.
Next, we show that pyruvate, at the concentrations present in
DMEM-F12 and other standard media, induces a pseudohypoxic re-
sponse mediated by HIF1a stabilization. Different from previous re-
ports (14, 15), the HIF1a stabilization observed in 21% oxygen was
independent of the rate of aerobic glycolysis, which is comparable in
Plasmax and DMEM-F12 (Fig. 4A), but dependent on the concentra-
tion of exogenous pyruvate (Fig. 3I), which may affect the activity of
prolyl hydroxylases that regulate the stability of HIF1a (15).–10 –5 0 5 10
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Fig. 5. Cells cultured in Plasmax approximate the in vivo tumor metabolome better. (A) Schematic representation of the experimental setup applied to compare
the untargeted metabolic profiling of CAL-120 cells cultured in vitro (as 2D monolayers or 3D spheroids) in Plasmax and DMEM-F12, with CAL-120–derived orthotopic
tumors. (B) PCA of three independent experiments or n = 3 mice (nine tumor fragments) performed as detailed in (A). (C) Weighted distance between each culture
condition and the mean values of tumor samples, as calculated from the PCA reported in (B). P values refer to a two-tailed t test for unpaired homoscedastic samples. a.u.,
arbitrary units. (D to F) Relative abundance and ratio of urea cycle intermediates in CAL-120 cells grown in Plasmax and DMEM-F12 as 2D and 3D cultures and orthotopic
mammary tumors. Means ± SEM; n = 3 independent experiments or n = 3 mice. P values refer to a two-tailed t test for unpaired homoscedastic samples comparing the in vitro
conditions to the tumor samples. (G to I) Micrographs of CAL-120–derived mammary tumor tissue showing (G) hematoxylin and eosin (H&E) staining and IHC for (H) Ki67
and (I) ASS1. Arrows indicate stromal cells, whereas the arrowhead denotes vessel endothelium. T, tumor; FP, fat pad.9 of 14
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 In addition, we discovered that concentrations of arginine typically
found in commercial media (~0.7 mM) reverse the activity of the urea
cycle enzyme ASL in the three TNBC cell lines analyzed in this work
(Fig. 4, L to O). Tracing supraphysiological concentrations of 13C6 ar-
ginine showed that the urea cycle is truncated in these cell lines at the
level of the mitochondrial reactions (OTC or CPS1) and at the ASS1-
catalyzed reaction (CAL-120). The reversal of the ASL-catalyzed reac-
tion has been previously reported in fumarate hydratase-deficient cells,
where the high intracellular concentration of fumarate favors the syn-
thesis of argininosuccinate from arginine (16). While, in such context,
the reversed activity of ASL could have a physiopathological justifica-
tion, the same reaction triggered by the excessive arginine supplemen-
tation has no relevance to tumor biology. Our findings indicate that,
under physiological conditions, ASS1-proficient TNBC cells mainly
use exogenous citrulline, and not arginine or arginine-derived orni-
thine, for the production of argininosuccinate (Fig. 4, M to O, and
fig. S3). In ASS1-deficient cells, excessive arginine availability masks
their distinctive metabolic traits: impaired coupling of citrulline to as-
partate and consequent low argininosuccinate levels (Fig. 4I).
However, comparing only in vitro conditions prevents unambiguous
conclusions on their relevance to tumor biology. Therefore, we com-
pared the metabolism of CAL-120 breast cancer cells grown in vitro as
adherent monolayers or as anchorage-independent spheroids, in both
DMEM-F12 and Plasmax, to an orthotopic mouse model of breast
cancer (Fig. 5).While previous reports showed that anchoragewithdraw-
al is sufficient to rewire the tricarboxylic acid cycle of cultured cancer cells
(17) or identifiedmetabolic vulnerabilities of cancer cells using advanced
culture systems (18), this is, to our knowledge, the first attempt to directly
compare the general metabolic profiles of cells cultured in different
media with an in vivo cancer model. Although the relative comparison
of metabolite levels measured in different biological matrices (i.e.,
cultured cells versus tumors) requires careful normalization and should
be cautiously interpreted, the levels of argininosuccinate indicated that
these ASS1-deficient cells do not reverse the ASL-catalyzed reaction
in vivo, as they do when cultured in nonphysiological media (Fig. 5E).
This is corroborated by the argininosuccinate/citrulline ratio, a
normalization-independent index of ASS1 activity (Fig. 5F). Together,
this provides proof of principle that the use of a physiological medium,
such as Plasmax, can prevent in vitro artifacts that would otherwise
require experimental work with laboratory animals to be disproved.
While specific metabolic parameters of tumors can be better ap-
proximated by either 3D culture conditions [e.g., citrate metabolism
(17)] or use of a physiological medium (e.g., urea cycle reversal, as
shown here), their combination represents a better model of the overall
metabolic profile of tumor cells. We can speculate that the remaining
gap between tumors and in vitro conditions could be further bridged by
taking into account the metabolic differences between murine and hu-
man blood, the composition of interstitial fluid, and the organ- and
stroma-specific (19) metabolic environment. However, a robust untar-
getedmetabolic comparison betweenmammary tumors grown inmice,
and cancer cells cultured under different in vitro conditions, proved that
a culture medium based on the composition of human blood is a signi-
ficant improvement compared to current standards.
In conclusion, we have shown that a physiologically formulatedme-
dium can provide new insights into the role of trace elements in cancer
biology, prevents artifacts imposed by the unbalanced nutritional
composition of conventional media, improves the degree to which in
vitro models reflect the metabolism of tumors, and may offer opportu-
nities for reduced use of animal models in cancer biology.Vande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019MATERIALS AND METHODS
Plasmax production
The components of Plasmax are reported in table S1. Stock solutions
were prepared in individual tubes for single use and stored at −78°C.
To increase the solubility of its components, the pH of solution 1 was
adjusted to 1.00 withHCl, and the pH of solution 4 (urate) was adjusted
to 13.30withNaOH.To prepare a bottle of Plasmax, stock solutions 1 to
5 were added to 500 ml of commercially available EBSS (cat. no.
24010043; Thermo Fisher Scientific, MA, USA), in combination with
L-glutamine (cat. no. 25030081; Thermo Fisher Scientific), sodium pyr-
uvate (S8636; Sigma-Aldrich,MO,USA), and 2.5%FBS (ThermoFisher
Scientific). After preparation and equilibration with 5% CO2, the pH of
different batches of Plasmax was 7.1 to 7.3, with thus not needing for
further adjustment. The buffering capacity of Plasmax ensured that its
pH remained stable whenMDA-MB-468 cells (seeded at 200,000 cells
per well) were cultured in 8 ml of medium for 72 hours. The osmolar-
ity of Plasmax was 280 mOsm/kg as measured with a vapor pressure
osmometer (Wescor 5500). Trace elements (including sodium sele-
nite; table S1) were supplemented at the concentrations found in Ad-
vanced DMEM-F12 (cat. no. 12634028; Thermo Fisher Scientific).
Cell culture
The following human TNBC cell lines were used: BT549 and MDA-
MB-468 (both obtained from A. Schulze, Biocenter, Wurzburg,
Germany, and originally purchased from the American Type Culture
Collection, VA,USA) andCAL-120 (DSMZ, Braunschweig, Germany).
All cell lines were authenticated using the Promega GenePrint 10 Kit
(Promega,WI,USA) and tested negative formycoplasma infection using
the MycoAlert Mycoplasma Detection Kit (Lonza, Bazel, Switzerland).
Before performing experiments to compare different media, cells
weremaintained inDMEM-F12 (cat. no. 21331046; Thermo Fisher Sci-
entific) supplemented with 2mM glutamine (Thermo Fisher Scientific)
and 10% FBS (Thermo Fisher Scientific). Cells were cultured at 37°C
and 5%CO2. To determine the doubling time,MDA-MB-468 cells were
cultured in DMEM-F12 and Plasmax supplemented with 2.5% FBS for
at least 10 consecutive passages. At each passage, the cells were trypsi-
nized and counted, and the same number of cells (500,000 or 1,000,000)
were seeded in a 10-cm dish with the respective media and allowed to
grow until 80% confluent. For the identification of the Plasmax
component responsible for HIF1a stabilization, BT549 cells were pre-
incubated in DMEM-F12 or Plasmax (both supplemented with 2.5%
FBS) for 2 days and subsequently (day 2) seeded in six-well plates at
50,000 cells per well in 2 ml of the respective culture medium. After
24 hours (day 3), culture medium was changed to 8 ml of medium
(DMEM-F12, DMEM, or RPMI 1640 for cells preincubated in DMEM-
F12; Plasmax for cells preincubated in Plasmax) with different concen-
trations of pyruvate. Cells were allowed to proliferate for 72 hours, after
which cell lysates were prepared (day 6) for immunoblotting.
Immunoblotting
Cells were lysed in Laemmli sample buffer (Bio-Rad, CA, USA) sup-
plemented with 2-mercaptoethanol. Lysates were heated at 95°C for
5 min and loaded on 10% gels (Bio-Rad) for SDS–polyacrylamide gel
electrophoresis. After electrophoretic separation, proteins were
transferred onto 0.2 mm nitrocellulose membranes (Amersham,
Germany), blocked with 5% nonfat milk [in tris-buffered saline (TBS) +
0.01% Tween], and incubated overnight at 4°C with the following
primary antibodies: ACTIN (1:500; SC1616; Santa Cruz, TX, USA),
ASS1 (D4O4B) XP (1:1000; cat. no. 70720; Cell Signaling, MA, USA),10 of 14
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 GPX4 (1:1000; ab125066, Abcam, Cambridge, UK), HIF1a (1:500; cat.
no. 610959, BD Biosciences, CA, USA), and PDK1 (1:1000; MSP49;
MitoSciences, OR, USA). Membranes were washed and incubated
with near-infrared fluorescent secondary antibodies (1 hour at room
temperature; 1:5000; LI-COR, NE, USA). Proteins were detected
with the LI-COR Odyssey Imaging System.
Immunohistochemistry
Tissue sections (4 mm) were cut from formalin-fixed, paraffin-
embedded blocks. These sections were baked onto poly-lysine slides
at 60°C before one set was stained with H&E to investigate morphology
and check suitability for further investigation. The following antibodies
were used for IHC: Ki67 (RM-9106; Thermo Fisher Scientific) and
ASS1 (cat. no. 70720; Cell Signaling). The sections were deparaffinized
in xylene, rehydrated through graded ethanols, andwashed in deionized
water before undergoing heat-induced epitope retrieval using a Dako
pretreatment module. All sections were heated for 25 min at 98°C in
10mM sodium citrate (pH 6) retrieval buffer (TA-250-PM1X, Thermo
Fisher Scientific). Sections were washed in TBS with Tween (TBST).
The staining took place on a Dako Autostainer Link 48. The antibodies
against Ki67 and ASS1 were used at 1:100 and 1:1000 dilutions, re-
spectively. Sections were then incubated with Dako EnVision rabbit
secondary antibody, washed with TBST, and stained with Dako liquid
diaminobenzidine. The sections were counterstained with hematoxylin,
taken through graded alcohols, xylene, and then a glass coverslip applied
withDPXmountant formicroscopy (CellPath). Slides were scannedwith
a Leica SCN400F slide scanner (Leica Biosystems, Wetzlar, Germany),
and images were acquired through the Leica Digital Image Hub.
In vivo models
All in vivo experiments were carried out in dedicated barriered facilities
proactive in environmental enrichment under the EU Directive 2010
and Animal (Scientific Procedures) Act 1986 (Home Office Project Li-
cense number: 60-4181) with ethical review approval (University of
Glasgow). Animals were cared for by trained and licensed individuals.
Statistical analysis
Unless explicitly stated, three independent biological experiments were
performed. Statistical analyses were performed with GraphPad Prism 7
using two-tailed, homoscedastic Student’s t tests for unpaired or paired
samples as indicated in the figure legends or a Pearson correlation test as
shown in Figs. 3D and 4B. Statistical analysis of RNA-seq was per-
formed as described below.
RNA sequencing
BT549, CAL-120, and MDA-MB-468 cells were preincubated in
DMEM-F12or Plasmax (both supplementedwith 2.5%FBS) for 2 days.
Subsequently (day 2), cells were seeded in six-well plates at 50,000 cells
per well (BT549 and CAL-120) or 100,000 cells per well (MDA-MB-
468) in 2 ml of the respective culture medium. After 24 hours (day
3), culture medium was changed to 8 ml of the respective medium,
and cells were further incubated for 72 hours under atmospheric
(21% O2, normoxia) or hypoxic (0.1% O2, hypoxia) conditions. On
day 6, cell number was determined using a Coulter counter (n = 3 wells
per condition), and cells were harvested for RNA extraction [n = 1 well
per condition; samples were processed using the QIAshredder/RNeasy
Mini Kit (Qiagen)].
For RNA-seq, samples were processed with on-column deoxy-
ribonuclease digestion and diluted to 1.5 mg of RNA per 50 ml of wa-Vande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019ter, and the quality of the purified RNA was tested on an Agilent
2200 TapeStation using RNA screentape. Libraries for cluster gener-
ation and DNA sequencing were prepared following an adapted
method from Fisher et al. (20) using Illumina TruSeq RNA Library
Preparation Kit v2. Quality and quantity of the DNA libraries were
assessed on anAgilent 2200 TapeStation (D1000 screentape) andQubit
(Thermo Fisher Scientific), respectively. The libraries were run on the
IlluminaNextSeq 500 using theHighOutput 75 cycles kit (2 × 36 cycles,
paired-end reads, single index). Quality control of the raw RNA-seq
data files was performed by FastQC (www.bioinformatics.babraham.ac.
uk/projects/fastqc/) and fastq_screen (www.bioinformatics.babraham.ac.
uk/projects/fastq_screen/). Then, RNA-seq reads were aligned to the hu-
man genome (GRCh38.75) using TopHat2 (21), and resulting bam
files were processed with htseq_count (https://htseq.readthedocs.io/en/
release_0.10.0/). The final counts were normalized and analyzed
with DESeq2 (22). Statistically significant differences in gene ex-
pression were determined with an FDR of 10%. In the PCA, the
first principal component explains 85.1% of the variance. The sec-
ond, third, and fourth components explain 8.9, 5.8, and 0.1% of
the variance, respectively.
Colony formation assays
BT549, CAL-120, and MDA-MB-468 cells were preincubated in
DMEM-F12 or Plasmax (both supplemented with 2.5% FBS) for 2 days
for the experiments reported in Fig. 1, and for all experiments, cells were
seeded in six-well plates in 2 ml of medium. Cell densities, incubation
times, and components added to the media are indicated in Figs. 1 and
2. Fresh medium was added after 96 hours to prevent nutrient exhaus-
tion. At endpoint, colonies were fixed with trichloroacetic acid (final
concentration of 3%, 30 min incubation at room temperature), washed
withwater, and stainedwith sulforhodamine B (0.057% in 1%acetic acid,
1 hour incubation at room temperature). LI-COR Odyssey and Image
Studio 5 were used for image acquisition, and ImageJ was used for
quantification of area covered by colonies and colony number. For
the identification of sodium selenite as a stimulator of colony forma-
tion, MDA-MB-468 cells were cultured in a mixture of DMEM-F12
and Plasmax (1:1) and in DMEM-F12 supplemented with the differ-
ent Plasmax stock solutions or individual Plasmax components re-
ported in table S1.
Lipid peroxidation assay
MDA-MB-468 cells were seeded at low (2000 cells/cm2) or high
(10,000 cells/cm2) cell density in DMEM-F12 in the presence or ab-
sence of 50 nM sodium selenite. After a 48-hour incubation, cells were
incubated with 1 mMBODIPY 581/591 C11 (Thermo Fisher Scientific)
for 15 min. Cells were washed three times with phosphate-buffered
saline (PBS), trypsinized, and resuspended in PBS with EDTA
(ethylenediaminetetraacetic acid) and DAPI (4′,6-diamidino-2-
phenylindole) before fluorescence-activated cell sorting (FACS)
analysis (excitation, 488 nm). Lipid peroxidation was assayed in
10,000 events by the change in fluorescence and represented as
the ratio Em510nm/Em590nm. As a positive control for lipid per-
oxidation, cells seeded at high cell density were exposed to 50 mM t-
butOOH for 1 hour and analyzed by FACS, as described, or incubated
for an additional 23 hours to assay the effect on cell survival.
GPX expression and activity analysis
MDA-MB-468 cells were seeded at low (2000 cells/cm2) or high
(10,000 cells/cm2) cell density in DMEM-F12 in the presence or11 of 14
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 absence of 50 nM sodium selenite. After a 72-hour incubation, cell
lysates were prepared in radioimmunoprecipitation assay buffer for
immunoblotting as described above, or GPX activity was analyzed
using the Glutathione Peroxidase Assay Kit (ab102530; Abcam) as
per the manufacturer’s instructions.
Targeted metabolic analysis
BT549, CAL-120, and MDA-MB-468 cells were cultured in DMEM-
F12 or Plasmax, and exchange rates/intracellular concentrations of nu-
trients and metabolites were determined. Cells were preincubated in
DMEM-F12 or Plasmax (both supplemented with 2.5% FBS) for
3 days. Subsequently, on day 3, cells were seeded in six-well plates at
100,000 cells per well (BT549 and CAL-120) or 200,000 cells per well
(MDA-MB-468) in 2 ml of the respective culture medium. After
24 hours (day 4), 2 ml of culture medium was added to each well
to prevent nutrient exhaustion. On day 5, culture medium was
changed to 2 ml (for medium extractions to calculate exchange rates)
or 7 ml (for cell extractions to determine intracellular metabolite
concentrations). At this time point, parallel wells were harvested
for protein determination (see mg prot day5 in the equation below).
Different volumes of culture media per well allowed quantification
of the exchange rates for metabolites with slow flux and, in parallel,
prevented artifacts when measuring intracellular levels of avidly
consumed metabolites. After 24 hours (day 6), medium and cell
extracts were prepared. Medium extracts: Twenty microliters of
culture medium (spent medium or concomitantly incubated cell-
free medium) was added to 980 ml of a cold extraction solution
(−20°C) composed of methanol, acetonitrile, and water (5:3:2). Cell
extracts: Cells were rapidly washed three times with ice-cold PBS, after
which intracellular metabolites were extracted with 600 ml of ice-cold
extraction solution for 5 min at 4°C. Medium and cell extracts were
centrifuged (10 min at 16,000g) to remove insoluble material, and the
supernatant was collected for LC-MS analysis. To allow data normal-
ization and estimation of secretion/consumption rate, protein concen-
trations were determined on days 5 and 6 using a modified Lowry
protein assay.
The LC-MS was performed as described previously (23). Briefly,
a Q Exactive Plus Orbitrap Mass Spectrometer (Thermo Fisher Sci-
entific) was used with a resolution of 35,000 at 200 mass/charge
ratio (m/z), electrospray ionization, and polarity switching mode
to enable both positive and negative ions across a mass range of 75
to 1000 m/z, and it was coupled with a Thermo Ultimate 3000 high-
performance liquid chromatography (HPLC) system. The HPLC
setup consisted of a ZIC-pHILIC column (SeQuant; 150 mm by
2.1 mm, 5 mm; Merck KGaA, Darmstadt, Germany), with a ZIC-
pHILIC guard column (SeQuant; 20 mm by 2.1 mm). Biological
extracts were injected (5 ml), and compounds were separated with
a mobile phase gradient of 15 min, which started with 20% ammo-
nium carbonate [20 mM (pH 9.2)] and 80% acetonitrile, and termi-
nated with 20% acetonitrile. Flow rate and column temperature were
maintained at 200 ml/min and 45°C, respectively, for a total run time
of 23 min. All metabolites were detected using lock masses and a
mass accuracy below 5 ppm. Thermo Xcalibur was used for data ac-
quisition, and LCquan or TraceFinder 3.2 was used for analysis. The
peak areas of metabolites were determined by using the exact mass
of the singly charged ions. The retention time of metabolites was
predetermined on the pHILIC column by analyzing an in-house
mass spectrometry metabolite library, which includes the IROA
Sigma-Aldrich MSMLS. The exchange rate per day [secretion (+)Vande Voorde et al., Sci. Adv. 2019;5 : eaau7314 2 January 2019or consumption (−)] for a specific metabolite (x) was obtained
according to the following equation
x ¼ Dmetaboliteðmg prot day5þ mg prot day6Þ=2
where Dmetabolite = ((x)nmolspent medium − (x)nmolcell-free medium).
The total consumption of amino acid–derived nitrogen was
calculated by adding up the consumption of each individual amino
acid multiplied by its number of nitrogen atoms.
13C6 arginine tracing
Cells were seeded in six-well plates at 100,000 cells per well (BT549 and
CAL-120) or 200,000 cells per well (MDA-MB-468) in 2ml of DMEM-
F12 or Plasmax (both supplemented with 2.5% FBS). After 24 hours
(day 1), culture medium was changed to 8 ml of DMEM containing
700 mM 13C6 arginine (Cambridge Isotope Laboratories, MA, USA)
(cells seeded in DMEM-F12) or Plasmax (as such or supplemented to
700 mMArgwith 13C6 arginine; cells seeded in Plasmax). After 48 hours
(day 3), cells were extracted in 400 ml of ice-cold extraction solution, and
samples were analyzed by LC/MS as described above.
Untargeted metabolic profiling of cell monolayers, 3D
spheroids, and tumors
CAL-120 cells were grown as 2D monolayers, and cell extracts for me-
tabolomics were prepared as described above. Cells were extracted in
400 ml of ice-cold extraction solution. For each of the three independent
experiments, cell extracts of three wells per condition were combined,
and the protein content was determined in three wells incubated in
parallel. All cell extracts were normalized to 2.16 ml of extraction solu-
tion per microgram of protein before LC-MS/MS analysis.
CAL-120 cells were seeded inDMEM-F12 or Plasmax (both supple-
mented with 2.5% FBS) at 4 × 106 cells per 200ml of culturemedium in
glass spinner flasks (40 rev/min; cat. no. F7689; Techne; Cole-Parmer
Ltd., UK) to allow sphere formation. After 72 hours (day 3), the cell
cultures were supplemented with 100 ml of the respective medium to
prevent nutrient exhaustion. On day 4, spheres were collected and em-
bedded in paraffin for IHC or used for extraction of metabolites.
Spheres were allowed to sediment, and culture medium volume was re-
duced to 1ml. After a brief centrifugation step (1 min, 600g), the super-
natant was removed, spheres were washed quickly with 1ml of ice-cold
PBS and centrifuged for 10 s, and the pellet was extracted in 1ml of ice-
cold extraction solution (vortexed briefly, and incubated for 5min at 4°C).
After centrifugation (10min at 16,000g), the supernatant (cell extract) was
collected for LC-MS/MS analysis, and the pellet was used to determine the
protein content with a modified Lowry protein assay. Before LC-MS/MS
analysis, cell extracts were diluted to 2.16 ml of extraction solution per mi-
crogramof protein, normalizing the samples to the extracts obtained from
the 2D monolayers.
Female severe combined immunodeficient mice (n = 3; 7 to
8 weeks old; Charles River Laboratories) were injected in themammary
fat padwith 4 × 106 CAL-120 cells (cell suspension in 50 ml ofMatrigel).
Tumors were allowed to establish for 160 days, after whichmice were
humanely euthanized using schedule 1 methods. Tumors were
quickly resected, divided into fragments, and either fixed in 10%
neutral-buffered formalin for IHC or flash frozen on dry ice for ex-
traction of metabolites. Frozen tumor fragments (two to four fragments
per tumor; nine fragments in total) were weighed and dissociated in
cold extraction solution (40mg/ml) using ceramic beads and a Precellys12 of 14
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 homogenizer (Bertin Instruments, Montigny-le-Bretonneux, France).
After centrifugation (10 min, 16,000g), the supernatant was used for
LC-MS/MS analysis.
Samples were analyzedwith the same LC/MS setup described above.
However, for this experiment,metaboliteswere separated over a 30-min
mobile phase gradient, decreasing the acetonitrile content to 20%, at a
flow rate of 100 ml/min. The total analysis time was 40 min, and meta-
bolites were detected using the mass spectrometer at a resolution of
70,000 (at 200m/z). A pooled sample comprising a mixture of all sam-
ple extracts was analyzed using the sameHPLC conditions but running
the mass spectrometer in single ionization mode to acquire the positive
and negative ions in separate runs and using data-dependent fragmen-
tation (ddMS2) to improve the confidence in metabolite identification.
Data were analyzed using Compound Discoverer software (Thermo
Scientific v2.1). Retention times were aligned across all sample data files
(maximum shift, 3 min; mass tolerance, 5 ppm). Unknown compound
detection (minimum peak intensity of 3 × 106) and grouping of com-
pound adducts were carried out across all samples (mass tolerance,
5 ppm; retention time tolerance, 0.7 min). Missing values were filled
using the software’s Fill Gap feature (mass tolerance, 5 ppm; signal/
noise tolerance, 1.5). Compound identification was achieved by
matching themass and retention time of observed peaks to an in-house
database generated using metabolite standards (mass tolerance, 5 ppm;
RT tolerance, 0.5 min). Peak annotations were further confirmed using
mzCloud (ddMS2) database search (precursor and fragment mass
tolerance, 10 ppm; match factor threshold, 50). Within Compound
Discoverer, data were normalized using a constant median strategy, and
PCA was also performed using only features identified by the above
strategy (in-house database and mzCloud). The weighted distance of
in vitro conditions to tumor samples was calculated using the following
equation
Weighted distance
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ððPC1repn  PC1tummeanÞ  0:49Þ2 þ ððPC2repn  PC2tummeanÞ  0:218Þ2
q
where PC1repn is the PC1 value of each in vitro replicate and PC1tummean
is the mean PC1 value of all tumor samples. 15, 2019SUPPLEMENTARY MATERIALS
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Fig. S1. Selenite-dependent colony formation.
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